LeMaitre Vascular, Inc. Form 4 Filings

LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. Pellegrino Joseph P JR reported acquisition or exercise transactions in this Form 4 filing.

LEMAITRE VASCULAR INC (LMAT) reported that director Joseph P. Pellegrino, Jr. received several small awards of dividend equivalent rights on September 3, 2026, each tied to previously granted restricted stock unit and performance share unit awards. Each right is the economic equivalent of one share of common stock and vests proportionately with the underlying award.

LeMaitre Vascular Inc (LMAT) director Lawrence J. Jasinski reported the acquisition of several small blocks of Dividend Equivalent Rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards and are the economic equivalent of LeMaitre common shares, vesting proportionately with the underlying awards. No Rule 10b5-1 trading plan is reported.

LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. SHADAN MARTHA reported acquisition or exercise transactions in this Form 4 filing.

LEMAITRE VASCULAR INC (LMAT) director Martha Shadan reported several small awards of Dividend Equivalent Rights on September 3, 2026. These derivative rights accrued on previously granted restricted stock unit and performance share unit awards from December 2023, December 2024, and December 2025 and vest proportionately with those awards. Each right is the economic equivalent of one share of common stock, and no Rule 10b5-1 trading plan is reported.

LEMAITRE VASCULAR INC (LMAT) director John James O'Connor reported five acquisitions of dividend equivalent rights on September 3, 2026. The awards total a small fractional interest in common stock and all are direct derivative holdings tied to previously granted restricted stock unit and performance share unit awards.

According to the footnotes, each dividend equivalent right is the economic equivalent of one share of common stock and accrues on outstanding equity awards, vesting proportionately with those awards. No Rule 10b5-1 trading plan is reported, and no sales or disposals are listed in this filing.

LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.

LEMAITRE VASCULAR INC (LMAT) reported that its Chief Financial Officer, Dorian Paul LeBlanc, received small awards of additional Dividend Equivalent Rights on September 3, 2026 tied to prior restricted stock unit (RSU) grants. The awards reflect accrued dividend equivalents and are the economic equivalent of additional shares of common stock.

LEMAITRE VASCULAR INC (LMAT) reported that Chairman and CEO George W. LeMaitre acquired several small blocks of Dividend Equivalent Rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards from December 2022, December 2023, December 2024, and December 2025 and will vest proportionately with those underlying awards. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular’s common stock, and no Rule 10b5-1 trading plan is reported in connection with these accruals.

LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. Kamke Trent G reported acquisition or exercise transactions in this Form 4 filing.

LEMAITRE VASCULAR INC (LMAT) reported that Senior V. P., Operations, Trent G. Kamke received multiple dividend equivalent rights awards on September 3, 2026. The awards, in small fractional amounts tied to prior restricted stock unit and performance share unit grants, are each the economic equivalent of one share of common stock and vest proportionately with the underlying awards. No Rule 10b5-1 trading plan is reported.

LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. Roush John A reported acquisition or exercise transactions in this Form 4 filing.

LEMAITRE VASCULAR INC (LMAT) reported that director John A. Roush received multiple small grants of dividend equivalent rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards from December 2023, December 2024, and December 2025.

Each dividend equivalent right is disclosed as the economic equivalent of one share of common stock and will vest proportionately with the underlying stock unit or performance share awards. No cash price was paid for these derivative awards, and no Rule 10b5-1 trading plan is reported.

LEMAITRE VASCULAR INC (LMAT) director John A. Roush exercised employee stock options on September 1, 2026 to acquire 3,444 shares of common stock at an exercise price of $48.60 per share. Following the transaction, he held 7,386 shares directly and 181 shares indirectly through his wife. No Rule 10b5-1 trading plan is reported.

LeMaitre Vascular director Lawrence J. Jasinski reported grants of dividend equivalent rights on existing equity awards. On 2026-06-04, he acquired several small blocks of dividend equivalent rights linked to previously granted restricted stock unit and performance share unit awards from 2023, 2024, and 2025.

Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the underlying awards. These are compensation-related accruals with no open-market buying or selling and no cash exercise price.

LeMaitre Vascular director John James O’Connor reported routine compensation-related grants of dividend equivalent rights. On June 4, 2026, he acquired several small awards of dividend equivalent rights tied to existing restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and carries a stated price of $0.00 per right. Following these transactions, O’Connor directly holds 5.0674 dividend equivalent rights in total, which vest proportionately with the underlying stock and performance awards rather than representing open-market purchases or sales.

Roush John A reported acquisition or exercise transactions in this Form 4 filing.

LeMaitre Vascular director John A. Roush reported routine compensation-related transactions in the form of dividend equivalent rights on June 4, 2026. Five separate grants of dividend equivalent rights were credited in fractional amounts, each tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests in step with the underlying equity awards. These awards involve no cash paid by Roush and do not reflect any open-market purchases or sales of shares.

LEMAITRE VASCULAR INC director Martha Shadan reported compensation-related awards of dividend equivalent rights tied to prior equity grants. On 2026-06-04, she acquired five derivative positions labeled as Dividend Equivalent Rights, each economically equivalent to one share of common stock and carrying no exercise price.

The rights accrued on restricted stock unit and performance share unit awards originally granted on 12/8/2023, 12/6/2024, and 12/10/2025, and will vest proportionately with those underlying awards. No open-market purchases or sales were reported, and all transactions were classified as grants or awards.

LeMaitre Vascular director Joseph P. Pellegrino Jr. reported several compensation-related grants of Dividend Equivalent Rights tied to existing equity awards. On June 4, 2026, he acquired small fractional rights on multiple restricted stock unit and performance share unit awards from prior grant dates.

Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying award. The transactions are coded as awards (not open‑market trades), so they reflect routine accrual of additional rights rather than buying or selling shares in the market.

LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.

LeMaitre Vascular’s Chief Financial Officer, Dorian Paul LeBlanc, received additional equity-linked compensation. On June 4, 2026, he was granted 3.1523 dividend equivalent rights tied to a restricted stock unit award granted on March 10, 2025, bringing his holdings in those rights to 5.8193. He also received 2.4759 dividend equivalent rights tied to a separate restricted stock unit award granted on December 10, 2025, increasing those holdings to 13.8976 dividend equivalent rights. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the related restricted stock unit awards.

LEMAITRE VASCULAR INC President and Director David B. Roberts reported routine compensation-related transactions involving dividend equivalent rights on June 4, 2026. These are derivative awards that mirror dividends on previously granted stock-based awards rather than open-market trades.

The filing shows nine acquisitions coded as grants, each adding small fractional dividend equivalent rights tied to restricted stock unit and performance share unit awards granted on December 12, 2022, December 8, 2023, December 6, 2024, February 18, 2025, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of common stock and vests proportionately with its underlying award. No shares were bought or sold in the market.

Kamke Trent G reported acquisition or exercise transactions in this Form 4 filing.

LeMaitre Vascular Inc. senior vice president of operations Trent G. Kamke reported multiple small awards of dividend equivalent rights on Dividend Equivalent Rights instruments. All seven transactions on June 4, 2026 are coded as grants or awards, reflecting compensation-related accruals rather than market purchases or sales.

Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and accrued on previously granted restricted stock unit and performance share unit awards from December 2022, December 2023, December 2024, and December 2025. The rights vest proportionately with the underlying equity awards, and there were no open-market buys or sells disclosed in this filing.

LEMAITRE VASCULAR INC Chairman and CEO George W. LeMaitre reported a mix of estate-planning and compensation-related equity movements in company securities. He made a bona fide gift of 11,974 shares of common stock, after which his direct holdings stood at 1,418,045 common shares. A related irrevocable life insurance trust for the benefit of his children holds 45,374 common shares, and he disclaims beneficial ownership except for any pecuniary interest. In addition, he received several small grants of dividend equivalent rights tied to prior restricted stock unit and performance share unit awards, each economically equivalent to one share of common stock and vesting proportionately with the underlying awards.

LeMaitre Vascular Chairman and CEO George W. LeMaitre reported open-market sales of company stock. On May 7 he sold 18,600 shares of common stock at a weighted average price of $107.6351 per share, and on May 8 he sold 27,881 shares at a weighted average price of $108.6905 per share.

After these direct sales, he continued to hold 1,430,019 shares directly. The filing also shows 33,400 shares held indirectly by the “LeMaitre Irrevocable Life Insurance Trust of 2025,” for the benefit of his children, where he disclaims beneficial ownership except for any pecuniary interest.

LeMaitre Vascular Senior Vice President of Operations Trent G. Kamke sold 2,928 shares of Common Stock in an open-market transaction on May 8, 2026. The weighted average sale price was $106.9969 per share, with trades ranging from $105.32 to $107.46. Following this sale, Kamke directly holds 3,749 shares.

LEMAITRE VASCULAR director Bridget A. Ross reported an exercise-and-sale transaction in company stock. On May 7, 2026, she exercised stock options to acquire a total of 5,044 shares of Common Stock, including 1,600 shares at an exercise price of $47.19 per share and 3,444 shares at $48.60 per share.

On the same date, she completed an open‑market sale of 5,044 Common Stock shares at a weighted average price of $111.0956 per share, executed in multiple trades ranging from $111.00 to $111.30. Following these transactions, she directly owns 3,942 Common Stock shares, and the reported options tied to these exercises are fully vested and, after exercise, no longer outstanding.

LeMaitre Vascular director Lawrence J. Jasinski reported an exercise-and-sell transaction in company stock. On May 7, 2026, he sold 3,943 shares of common stock in an open-market sale at $110.00 per share, leaving him with 4,714 directly held shares afterward.

On the same date, he exercised stock options to acquire a total of 2,858 common shares at exercise prices of $101.12, $54.65, and $47.19 per share. Related option entries show remaining option positions in multiple grants following these exercises. Overall, the filing reflects a combination of option exercises and a net sale of shares.

LeMaitre Vascular director Joseph P. Pellegrino Jr. exercised stock options to acquire 2,941 shares of Common Stock at $35.48 per share. These shares came from a fully vested option that was exercised in full, leaving no remaining derivative position from this grant. Following the transaction, he directly owns 15,021 Common shares, making this a routine compensation-related option exercise rather than an open-market purchase or sale.

LeMaitre Vascular director Martha Shadan reported equity-based compensation awards, not open-market trades. On March 26, 2026, she was granted several small blocks of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025.

Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying stock awards. All transactions are coded as awards or other acquisitions, with no reported share purchases or sales in the market.

LEMAITRE VASCULAR INC director Bridget A. Ross reported compensation-related awards of dividend equivalent rights tied to existing equity grants. On March 26, 2026, she acquired several small blocks of dividend equivalent rights, each economically equivalent to one share of common stock and linked to prior restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. These rights vest proportionately with the underlying awards and reflect routine equity compensation accruals rather than open-market trading.

LeMaitre Vascular director John James O'Connor reported grants of dividend equivalent rights linked to existing stock awards. On March 26, 2026, he acquired several small blocks of Dividend Equivalent Rights, each economically equivalent to one share of LeMaitre common stock.

The rights accrued on previously granted restricted stock unit and performance share unit awards from December 8, 2023, December 6, 2024, and December 10, 2025, and will vest proportionately with those underlying awards. These are compensation-related accruals rather than open‑market share purchases or sales.

LeMaitre Vascular director John A. Roush reported grants of dividend equivalent rights tied to prior equity awards. On March 26, 2026, he acquired several small fractional awards of Dividend Equivalent Rights, each economically equal to one share of LeMaitre Vascular common stock.

The rights accrued on restricted stock unit and performance share unit awards originally granted on December 8, 2023, December 6, 2024, and December 10, 2025, and they vest proportionately with those underlying awards. These are compensation-related accruals rather than open-market stock purchases or sales.

LEMAITRE VASCULAR INC director Lawrence J. Jasinski reported routine compensation-related grants of dividend equivalent rights. On March 26, 2026, he acquired several small fractional awards of dividend equivalent rights linked to existing restricted stock unit and performance share unit grants from December 8, 2023, December 6, 2024, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the underlying stock or performance awards. These are non-cash, derivative awards and do not represent any open-market share purchases or sales.

LeMaitre Vascular director Joseph P. Pellegrino Jr. reported multiple awards of dividend equivalent rights on derivative securities. On March 26, 2026, he acquired several small grants of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards.

Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying equity awards granted in 2022, 2023, and 2024–2025. These are compensation-related accruals, with no open-market purchases or sales reported in this filing.

LeMaitre Vascular (LMAT) President and Director David B. Roberts reported compensation-related grants of dividend equivalent rights on derivative awards. On March 26, 2026, he acquired multiple small blocks of Dividend Equivalent Rights, each economically equal to one share of common stock and priced at $0.0000 per right.

The footnotes explain these rights accrued on previously granted restricted stock units and performance share units from awards dated December 12, 2022, December 8, 2023, December 6, 2024, February 18, 2025, and December 10, 2025, and vest proportionately with those awards. No open‑market buys or sells were reported; this filing reflects routine equity-based compensation accrual rather than trading activity.

LeMaitre Vascular Senior Vice President of Operations Trent G. Kamke reported seven acquisitions of Dividend Equivalent Rights on March 26, 2026. Each right is economically equivalent to one share of LeMaitre common stock and is tied to previously granted restricted stock unit and performance share unit awards from 2022, 2023, 2024 and 2025, vesting in step with those underlying awards. These entries reflect routine, compensation-related accruals rather than open-market trading.

LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.

LeMaitre Vascular Chief Financial Officer Dorian Paul LeBlanc received additional dividend equivalent rights tied to existing restricted stock unit awards. On March 26, 2026, he was granted 2.0948 dividend equivalent rights related to an RSU award granted on March 10, 2025 and 2.6670 rights related to an RSU award granted on December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying RSUs. Following these awards, his holdings from these grants increased to 11.4217 and 2.6670 dividend equivalent rights, respectively.

LeMaitre Vascular’s Chairman and CEO, George W. LeMaitre, reported routine compensation-related awards rather than market trades. On March 26, 2026, he acquired several blocks of dividend equivalent rights, each economically equal to one share of LeMaitre Vascular common stock.

The rights accrued automatically on earlier restricted stock unit and performance share unit awards granted in December 2022, 2023, and 2024, and they will vest proportionately with those underlying awards. No open-market buying or selling occurred, and the transactions do not change cash holdings.

LeMaitre Vascular senior vice president Trent G. Kamke exercised stock options and sold the resulting shares. He exercised options for 2,625 shares of common stock at an exercise price of $35.48 per share, then sold 2,625 shares at $108.50 per share, leaving 6,677 shares owned directly.

LeMaitre Vascular’s President and Director David B. Roberts reported an open-market sale of 3,311.68 shares of common stock on March 11, 2026 at a weighted average price of $107.6752 per share. After this transaction, he directly holds 14,667.32 shares of the company’s common stock.

The sale was executed in multiple trades at prices ranging from $106.52 to $108.65, with the weighted average reported. Roberts has undertaken to provide detailed trade and pricing information to the company, its shareholders, or the SEC staff upon request.

LeMaitre Vascular’s Chief Financial Officer Dorian Paul LeBlanc reported routine equity compensation activity. On March 10, 2026, he exercised dividend equivalent rights into 2 shares of common stock at $0.00 per share and now holds 9.3269 dividend equivalent rights. He also holds 2,302 shares of common stock directly after these transactions.

The filing shows 96 shares of common stock were withheld at $109.20 per share to satisfy tax obligations on restricted stock units that vested from an award granted on March 10, 2025. The tax withholding is characterized as an exempt sale under Rule 16b-3(e) and does not reflect an open-market trade.

LeMaitre Vascular director Martha Shadan reported equity-based compensation on common stock. On February 26, 2026, she acquired 476 shares of common stock at a price of $0.0000 per share as a grant or award. She also acquired 1 additional common share through the exercise of a dividend equivalent right linked one-for-one to common stock. These transactions stem from a Performance Share Unit award originally granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remaining portions scheduled to vest in equal annual installments on the grant date anniversaries over the next two years.

LeMaitre Vascular director John A. Roush reported equity awards and vesting activity, not open‑market trades. On February 26, 2026, he received a grant of 476 shares of common stock and 1 share from the exercise of dividend equivalent rights, bringing his directly held common stock to 3,942 shares. Related derivative dividend equivalent rights totaled 2.8963 following settlement linked to a Performance Share Unit (PSU) award granted on December 6, 2024, which vested one‑third when the performance condition was met, with the remainder vesting in equal annual installments over the next two years. An additional 181 shares are held indirectly by his spouse.

LeMaitre Vascular director Bridget A. Ross reported acquiring company stock through equity awards. On February 26, 2026 she received 476 shares of common stock upon partial vesting of a performance share unit award, plus 1 share released from dividend equivalent rights, bringing her direct holdings to 3,942 shares.

LeMaitre Vascular director John James O'Connor reported equity awards and related conversions, not open-market trading. On February 26, 2026 he acquired 476 shares of common stock at $0.0000 per share as a grant or award, bringing his direct common stock holdings to 62,826 shares, then to 62,827 shares after a related derivative conversion.

He also exercised 1 dividend equivalent right and converted it into 1 share of common stock, and now holds 2.8963 dividend equivalent rights. Footnotes explain these transactions relate to a Performance Share Unit award granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remainder vesting in equal annual installments over the next two years.

LeMaitre Vascular director Lawrence J. Jasinski reported equity awards tied to performance share units. On February 26, 2026, he acquired 476 shares of common stock at no cost upon settlement of a PSU award granted on December 6, 2024, plus 1 additional common share from a derivative exercise.

The PSU award vested one‑third when the performance condition was determined satisfied on February 26, 2026, with the remaining two‑thirds vesting in equal annual installments over the next two years. Related dividend equivalent rights, economically equal to common stock, now total 2.8963 rights.

LEMAITRE VASCULAR director Joseph P. Pellegrino Jr. reported share acquisitions tied to equity compensation, not open-market buying or selling. On February 26, 2026, he received 1,893 shares of common stock as part of a performance share unit (PSU) award granted on December 6, 2024, after 25% of the award vested upon satisfaction of a performance condition.

He also acquired 4 dividend equivalent rights, which were exercised into 4 shares of common stock at a price of $0.00 per share. Each dividend equivalent right is the economic equivalent of one share of common stock and was released in connection with the PSU vesting. Following these transactions, he directly owned 12,080 shares of common stock and 11.4826 dividend equivalent rights, reflecting routine equity-based compensation rather than discretionary trading.

LeMaitre Vascular senior vice president Trent G. Kamke reported multiple equity transactions. On February 27, 2026, he completed an open-market sale of 1,044 shares of common stock at $110.29 per share, after which he directly held 6,677 common shares.

On February 26, 2026, he acquired 1,051 common shares at no cost from the settlement and partial vesting of a performance share unit award, plus 2 additional shares from related dividend equivalent rights. Also on that date, 93 shares were withheld to cover tax obligations tied to the PSU vesting.

LeMaitre Vascular (LMAT) president and director David B. Roberts reported multiple equity transactions. The largest was an open-market sale of 8,464 shares of common stock at a weighted average price of $106.8003 per share, leaving him with 17,979 shares directly owned after that sale.

On the prior day, he acquired common stock through the vesting and settlement of performance share unit (PSU) awards and related dividend equivalent rights, including grants of 1,514 shares and 146 shares at no cost, plus small amounts from dividend equivalents. The company also withheld 134 shares and 13 shares to cover tax obligations upon PSU vesting, which are reported as exempt dispositions.

LEMAITRE VASCULAR INC Chairman and CEO George W. LeMaitre reported a mix of stock sales, awards, and transfers. He sold an aggregate 205,930 shares of common stock in open-market transactions on February 26, 2026 and March 2, 2026, at weighted average prices of $106.7557 and $107.8137 per share, including sales made under a Rule 10b5-1(c) trading plan adopted on March 10, 2025.

On February 26, 2026, he received 5,609 shares upon settlement of a performance share unit award, plus 13 shares from related dividend equivalent rights, and 13 additional common shares from a derivative conversion. The company withheld 496 shares to cover tax obligations on the vesting PSUs.

On March 2, 2026, he made a bona fide gift transfer of 5,000 common shares. Separately, 33,400 shares are held by an irrevocable trust for the benefit of his children, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.

LeMaitre Vascular President and Director David B. Roberts reported exercising stock options and acquiring common shares of the company. On February 5, 2026, he exercised options for 2,672 shares at $37.29 and 7 shares at $48.60, receiving the same number of common shares.

Following these transactions, Roberts directly owned 24,930 shares of common stock. The option grants exercised were fully vested and exercisable, and after the transactions one option grant was fully used while another left 14,054 options outstanding.

LeMaitre Vascular’s Senior Vice President of Operations, Trent G. Kamke, reported exercising stock options and acquiring common shares. On January 8, 2026, he exercised options covering 1,229 shares of common stock at $37.29 per share and 1,115 shares at $48.60 per share. These transactions increased his directly held common stock to 5,646 shares after the first exercise and 6,761 shares after the second.

Following these exercises, he continued to hold stock options directly. After the first transaction, he held 3,690 stock options with a $37.29 exercise price, originally granted on December 2, 2020 and expiring on December 2, 2027. After the second, he held 5,085 stock options with a $48.60 exercise price, granted on December 11, 2021 and expiring on December 11, 2028. Footnotes state these options are fully vested and exercisable.

LeMaitre Vascular Inc. reported insider activity by its chairman and CEO, who is also a director, involving multiple transactions in company common stock on 12/11/2025 and 12/12/2025. The activity included exercises of stock options at exercise prices of $37.29, $48.6, $47.19 and $54.65, as well as releases of dividend equivalent rights that resulted in share acquisitions at $0 per share.

The filing notes that several dispositions reflect shares withheld by the issuer to cover tax obligations tied to vesting restricted stock units and performance stock units, treated as exempt sales under Rule 16b-3(e). It also records a transfer of 12,100 shares from the reporting person’s direct holdings to the LeMaitre Irrevocable Life Insurance Trust of 2025. After these transactions, the reporting person directly owns 1,682,304 common shares, and 33,400 shares are held indirectly by the trust.

LeMaitre Vascular, Inc. reported insider equity transactions by its president and director dated 12/11/2025 and 12/12/2025. The reporting person acquired small amounts of common stock at $0 per share through the release of dividend equivalent rights tied to earlier restricted and performance stock unit awards. On those same dates, the issuer withheld 297 and 302 shares on multiple transactions to cover tax withholding obligations triggered by the vesting of awards granted on 12/11/2021 and 12/12/2022. After all reported activity, the insider directly owned 22,251 shares of LeMaitre Vascular common stock.